Citizens JMP raised the firm’s price target on Evolent Health (EVH) to $13 from $12 and keeps an Outperform rating on the shares. Evolent’s Q4 ...

Full Year 2024 Results Key Financial Results Revenue: US$2.55b (up 30% from FY 2023).

Healthcare solutions company Evolent Health (NYSE:EVH) fell short of the market’s revenue expectations in Q4 CY2024, but ...

Q4 2024 Management View CEO Seth Blackley noted Evolent Health achieved $2.55 billion in revenue for 2024, reflecting a 30% growth over the prior year, and $160.5 million in adjusted EBITDA at the low ...

Evolent Health Inc . (NYSE:EVH) stock has reached its 52-week low, trading at $9.55, marking a significant downturn for the company within the healthcare sector. Despite the current market sentiment, ...

Shares of NYSE EVH opened at $10.44 on Friday. Evolent Health has a 1-year low of $9.45 and a 1-year high of $35.00. The company has a 50-day moving average of $10.75 and a two-hundred day moving ...

NYSE EVH opened at $10.44 on Friday. Evolent Health has a one year low of $9.45 and a one year high of $35.00. The stock has a 50-day moving average of $10.75 and a 200 day moving average of $18. ...

Reports Q4 revenue $646.5M, consensus $650.9M. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, “Evolent delivered ...

Evolent Health, Inc. ( NYSE: EVH) Q4 2024 Earnings Conference Call February 20, 2025 5:00 PM ET Seth Frank - Vice President, Investor Relations Seth Blackley - Chief Executive Officer John Johnson - ...

Evolent Health (EVH) came out with a quarterly loss of $0.02 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.23 per share a year ago. These figures are ...

Revenue of $646.5 million for the three months ended December 31, 2024 and $2,554.7 million for the year ended December 31, 2024, representing 16.3% and 30.1% growth ...

CEO Seth Blackley noted Evolent Health achieved $2.55 billion in revenue for 2024, reflecting a 30% growth over the prior year, and $160.5 million in adjusted EBITDA at the low end of the guidance ...